Saturday 17 October 2026
Export CGEM’s income statement to Excel — free account
Cullinan Therapeutics, Inc.
CGEM Healthcare Biotechnology
In the quarter to June 2026, EPS grew 24.3% and free cash flow grew 33.7%, each against the same quarter a year earlier.
12.93
1.07
−7.64%
Follow CGEM
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (50.30%) | (48.16%) | (44.02%) | (40.18%) |
+8 more TTM periods Free account |
|
| (46.30%) | (44.99%) | (41.09%) | (38.12%) | ||
ROIC |
0.00% | (1,051.43%) | (489.82%) | (127.05%) | |
Return on Tangible Assets |
(67.87%) | (67.68%) | (62.92%) | (69.95%) | |
Free Cash Flow per Share |
(2.59) | (2.95) | (2.98) | (2.95) | |
Free Cash Flow |
(159.25) | (178.64) | (175.80) | (174.35) | |
Capital Expenditures |
— | — | (0.05) | (0.09) | |
| Other line items | |||||
Cash ROIC |
(24.27%) | (24.88%) | (22.35%) | (22.24%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.78 | 0.81 | 0.80 | 0.80 | |
Depreciation/Fixed assets |
1.20 | 0.92 | 0.74 | 0.63 | |
Capex/Depreciation |
0.00 | 0.00 | (0.16) | (0.28) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.59) | (2.95) | (2.98) | (2.95) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates